Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, June 24, 2023

Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment

 

You mean your doctors and hospitals have completely failed at providing you recreational drugs for years for your stroke recovery? How fucking incompetent are they?


Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment

News


AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper

Published

Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment
DMT in powder form. Photo by DMTrott via Wikimedia Commons.

Algernon Pharmaceuticals Inc.’s (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) subsidiary Algernon Neuroscience will be the first company to test intravenous (IV) DMT on people suffering from traumatic brain injury or stroke.

On Monday, the clinical-stage pharmaceutical development company announced the successful completion of dosing in the final cohort of its Phase 1 clinical study involving AP-188 which is DMT.

AGN Neuro is the first company to test DMT at single escalating concentrations with an IV dose for a 6-hour duration. The safety review committee has confirmed no safety or tolerability issues with the highest dose.

This dose maintained plasma DMT concentrations at targeted levels and was below the established psychedelic dose.

The psychedelic dose of DMT was previously identified as 0.2 mg/kg by Dr. Rick Strassman, a DMT researcher and Algernon consultant, in his pioneering DMT human studies in the early 1990s.

DMT is believed to activate pathways involved in forming neuronal connections and has been shown to increase the number of dendritic spines on cortical neurons(Sounds very useful for stroke recovery). These spines form synapses with other neurons and are a critical site for neuronal transmission.

The Phase 1 trial was conducted at the Centre for Human Drug Research in Leiden, Netherlands. It aimed to identify the safety, tolerability and pharmacokinetics of sub-psychedelic doses of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours.

AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper.

“Neuroplasticity’s role in healing the brain after an injury is one of the most exciting areas of research globally in the pursuit of a treatment for stroke and TBI, and AGN Neuro is at the forefront of this work,” Algernon CEO Christopher J. Moreau said.

Read more: Algernon partners with Yale University for phase II DMT study

Read more: Small Pharma gets approval for upcoming injectable DMT trial on humans

Posted by at
Labels: , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)